Ansofaxine free base | CAS# 916918-80-4 (free base)

MedKoo Cat#: 581947 | Name: Ansofaxine free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ansofaxine, also known as toludesvenlafaxine, is a triple reuptake inhibitor, targeting serotonin, dopamine and norepinephrine. Toludesvenlafaxine had high binding affinity on SERT, NET and DAT, and significantly inhibited the reuptake of serotonin (IC50 = 31.4 ± 0.4 nM), norepinephrine (IC50 = 586.7 ± 83.6 nM) and dopamine (IC50 = 733.2 ± 10.3 nM) in vitro. Toludesvenlafaxine demonstrated significant antidepressant-like effects in rat models at 8-16 mg/kg. In addition, toludesvenlafaxine significantly reduced serum corticosterone and significantly increased testosterone levels in rats.

Chemical Structure

Ansofaxine free base

CAS#916918-80-4 (free base)

Theoretical Analysis

MedKoo Cat#: 581947

Name: Ansofaxine free base

CAS#: 916918-80-4 (free base)

Chemical Formula: C24H31NO3

Exact Mass: 381.2300

Molecular Weight: 381.52

Elemental Analysis: C, 75.56; H, 8.19; N, 3.67; O, 12.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

916918-84-8 (HCl) 2137075-66-0 (HCl hydrate) 916918-80-4 (free base)

Synonym

Ansofaxine; Toludesvenlafaxine; LPM570065; LPM 570065; LPM-570065; LY03005; LY-03005; LY 03005;

IUPAC/Chemical Name

4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenyl 4-methylbenzoate

InChi Key

QKYBZJLEMOZFFU-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H31NO3/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24/h7-14,22,27H,4-6,15-17H2,1-3H3

SMILES Code

O=C(OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1)C3=CC=C(C)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 381.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H. Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry. 2022 Jul;55(4):193-202. doi: 10.1055/a-1714-9097. Epub 2022 Jan 19. PMID: 35045580; PMCID: PMC9259184. 2: Mi W, Yang F, Li H, Xu X, Li L, Tan Q, Wang G, Zhang K, Tian F, Luo J, Xia J, Yuan K, Lu L, Deng J, Tian J, Zhang H. Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):252-260. doi: 10.1093/ijnp/pyab074. PMID: 34747448; PMCID: PMC8929756. 3: Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019 Jan 9;6:95-110. doi: 10.1016/j.ibror.2019.01.001. PMID: 31211282; PMCID: PMC6562183.